Yvette Cleland, CEO of Clinical Professionals, spoke to Suhail Mirza about her career to date and the importance of training and development in recruitment. “In their summer 2018 Harvard Business Review Article (entitled “Manage Your Work, Manage Your Life”) academics, Boris Groysberg and Robin Abrahams state that in order to achieve the mythical work/life balance, leaders
Senior QA SpecialistClinical ProfessionalsHertfordshire, UK
- FULL TIME
RA / QA SpecialistClinical ProfessionalsWarwickshire, UK
- FULL TIME
PV ScientistClinical ProfessionalsLondon East, UK
- FULL TIME
Senior Project Manager – New ProductsClinical ProfessionalsLondon East, UK
- FULL TIME
Europe’s Leading Life Science Staffing Business
Clinical Professionals is Europe’s leading pharmaceutical research and development recruitment company, with a focus on job placement in the scientific, pharmacology, clinical development and post approval services. We are dedicated to staffing in the Pharmaceutical, Biotechnology, Devices and CRO industries throughout Europe. Our client portfolio includes global leaders in pharmaceutical development and clinical research, whilst our expertise encompasses a wide remit of life science job sectors, including dedicated teams within clinical research, drug safety and pharmacovigilance jobs, medical communications jobs, QA/QC jobs, regulatory affairs jobs and medical affairs jobs. Clinical Professionals always provides candidates and clients with services of the highest ethical standards.
As Europe’s leading life science staffing agency, Clinical Professionals offer a unique array of services which include “Pipeline Watch” – our advisory consultation programme which is free for candidates, as well as our “Talent Tracker” service – a tracking database that lets us identify as well as track candidates across Europe that matches clients staffing needs in the future.
Clinical Professionals have now been successfully running the Graduate Training Academy for 2 years, which identifies, fully funds and trains the most talented Life Sciences University Graduates within the UK and places them into their first to industry role.
Clinical Professionals provide the candidates and client alike with the consultative approach of a specialist staffing organisation combined with the Pan-European coverage of an industry leading supplier. We provide our clients and candidates with unrivalled specialist understanding, knowledge and experience in the staffing needs of the life sciences industry.
Specialist Pharmaceutical Jobs Sectors
Clinical Professionals provide jobs within the Life Science community, being the most effective European online pharmaceutical jobs and careers management company in the pharmaceutical, clinical research, medical device, biotech and health care industries. Each of our consultants are strategically aligned to one of these specialist sectors which means that job seekers are assured they are working with consultants who have in-depth role and job knowledge and are experts at placing individuals in their chosen pharmaceutical job sector. Clinical Professional recruits for various clinical jobs including Pharmacovigilance, Regulatory Affairs, Biometrics, Health Economics, Medical Communication, Scientific and Medical Information.
Committed to improving the lives of patients by connecting talented professionals to the life science industry.
Clinical Professionals are affiliate members of APSCo
Contact us today to find out how we can progress your career to the next level
Lilly have reported positive results from two Phase lll trials, PRONTO-T1D and PRONTO-T2D, which examined the safety and efficacy of Ultra Rapid Lispro (URLi) compared to insulin lispro to treat people with type 1 and type 2 diabetes. The trial met the primary efficacy endpoint of non-inferior A1C reduction from baseline compared to insulin lispro
AstraZeneca has reported positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) of BMS-512148 compared to placebo for the treatment of patients with type 2 diabetes (T2D). The trial had met its primary safety objective of non-inferiority for major adverse cardiovascular events (MACE). The trial also achieved one of its two